Table 2.
Baseline comorbidity prevalence
| Vedolizumab (n = 203) | Ustekinumab (n = 207) | P‐value | |
|---|---|---|---|
| Charlson comorbidity index, N (%) | |||
| 0 | 154 (75.9) | 161 (77.8) | 0.247 |
| 1 | 26 (12.8) | 33 (15.9) | |
| 2 | 8 (3.9) | 6 (2.9) | |
| ≥3 | 15 (7.4) | 7 (3.4) | |
| Diabetes | |||
| Uncomplicated (1) | 7 (3.4) | 8 (3.9) | |
| End‐organ damage (2) | 2 (1.0) | 0 (0.0) | |
| Liver disease | |||
| Mild (1) | 0 (0.0) | 2 (1.0) | |
| Moderate to severe (3) | 4 (2.0) | 2 (1.0) | |
| Solid tumour | |||
| Localised (2) | 3 (1.5) | 1 (0.5) | |
| Metastatic (6) | 0 (0.0) | 0 (0.0) | |
| Leukaemia (2) | 0 (0.0) | 0 (0.0) | |
| Lymphoma (2) | 2 (1.0) | 1 (0.5) | |
| AIDS (6) | 0 (0.0) | 0 (0.0) | |
| Chronic kidney disease (2) | 8 (3.9) | 5 (2.4) | |
| Congestive heart failure (1) | 6 (3.0) | 1 (0.5) | |
| Myocardial infarction (1) | 9 (4.4) | 3 (1.4) | |
| Pulmonary disease (1) | 16 (7.9) | 7 (3.4) | |
| Peripheral vascular disease (1) | 1 (0.5) | 1 (0.5) | |
| CVA or TIA (1) | 4 (2.0) | 2 (1.0) | |
| Dementia (1) | 1 (0.5) | 0 (0.0) | |
| Hemiplegia (2) | 0 (0.0) | 0 (0.0) | |
| Connective tissue disease (1) | 11 (5.4) | 21 (10.1) | |
| Peptic ulcer (1) | 2 (1.0) | 4 (1.9) | |
| Total number of comorbidities | 76 | 58 | 0.523 |
Categories of CCI were compared between groups by using chi‐squared test, total number of comorbidities by using Mann‐Whitney U Test. Numbers next to each comorbidity represent number of points given according to CCI.
Abbreviations: AIDS, acquired immune deficiency syndrome; CVA, cerebrovascular accident; TIA, transient ischemic attack.